Holders — by stockHoldings — by fund
Eleva Capital SAS
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 2054496
$86.0M
disclosed book value
24
positions
324.5%
largest position share
Positions, as of 2026-06-30
top 24 of 24 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CRH PLC | 2.7M | $279.1M | 324.5% |
| 2 | AMER SPORTS INC | 298,802 | $9.8M | 11.4% |
| 3 | NVDANVIDIA CORPORATION | 52,002 | $9.1M | 10.5% |
| 4 | NFLXNETFLIX INC | 87,190 | $8.4M | 9.7% |
| 5 | GOOGLALPHABET INC | 27,967 | $8.0M | 9.4% |
| 6 | TSMTAIWAN SEMICONDUCTOR MFG LT | 21,411 | $6.5M | 7.6% |
| 7 | ANETARISTA NETWORKS INC | 46,957 | $5.8M | 6.7% |
| 8 | AMZNAMAZON COM INC | 16,155 | $3.4M | 3.9% |
| 9 | TMUST-MOBILE US INC | 14,347 | $3.0M | 3.5% |
| 10 | HOODROBINHOOD MKTS INC | 31,625 | $2.2M | 2.5% |
| 11 | ON HLDG AG | 50,150 | $1.7M | 2% |
| 12 | BSXBOSTON SCIENTIFIC CORP | 26,667 | $1.7M | 1.9% |
| 13 | SPOTIFY TECHNOLOGY S A | 2,715 | $1.3M | 1.5% |
| 14 | NEWAMSTERDAM PHARMA COMPANY | 25,721 | $823,329 | 1% |
| 15 | CGONCG ONCOLOGY INC | 8,289 | $561,000 | 0.7% |
| 16 | ESPERION THERAPEUTICS INC | 183,047 | $501,549 | 0.6% |
| 17 | MLYSMINERALYS THERAPEUTICS INC | 17,081 | $462,724 | 0.5% |
| 18 | FENCFENNEC PHARMACEUTICALS INC | 53,234 | $327,389 | 0.4% |
| 19 | IRONDISC MEDICINE INC | 5,115 | $327,053 | 0.4% |
| 20 | VRDNVIRIDIAN THERAPEUTICS INC | 7,126 | $139,385 | 0.2% |
| 21 | FCXFREEPORT MCMORAN INC | 2,258 | $132,725 | 0.2% |
| 22 | ACHRARCHER AVIATION INC | 21,534 | $111,331 | 0.1% |
| 23 | EWTXEDGEWISE THERAPEUTICS INC | 17,460 | $54,990 | 0.1% |
| 24 | AQSTAQUESTIVE THERAPEUTICS INC | 2,720 | $11,288 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.